The total return over the past 12 months is -71.04% vs. +16.94% for the S&P 500. So far it's up -47.39% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (71.04%) | (65.23%) | (57.41%) | N/A | N/A | N/A |
| Total Return CAGR | (71.04%) | (65.23%) | (57.41%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Acurx Pharmaceuticals, Inc. (ACXP)
| Year | Start price | End price | ACXP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.49 | $1.31 | (47.39%) | +14.51% | (61.90%) |
| 2025 | $16.28 | $2.49 | (84.71%) | +17.72% | (102.43%) |
| 2024 | $76.60 | $16.28 | (78.75%) | +24.89% | (103.64%) |
| 2023 | $79.60 | $76.60 | (3.77%) | +26.19% | (29.96%) |
| 2022 | $86.43 | $79.60 | (7.90%) | (18.17%) | +10.27% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
